MHRA latest to approve Zilbrysq for gMG treatment in adults

Following recent approvals in Europe and the USA, the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has now also granted marketing authorization for Zilbrysq (zilucoplan).

Developed by Belgian drugmaker UCB’s (Euronext: UCB), Zibrysq is approved as an add-on to standard therapy for the treatment of generalised myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive.

gMG is a rare autoimmune disease with a UK prevalence of 15 cases per every 1 million people. People living with the disease can experience a variety of symptoms, including severe muscular weakness that can result in double vision, drooping eyelids, difficulty with swallowing, chewing and talking, as well as life-threatening weakness of the muscles of respiration.